A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease

Inclusion Criteria

• •Have serologically confirmed GD as documented by presence of elevated stimulatory thyrotropin receptor antibody (TSH-R-Ab) level (i.e., \> specimen-to-reference ratio of 140%) at the Screening Visit.
• •Have active hyperthyroidism due to GD with the following laboratory values at the Screening Visit:
• •* TSH \< LLN
• •* FT3 \> upper limit of normal (ULN) and \<=5 \* ULN
• •* FT4 \> ULN and \<=5 \* ULN
• •Note: Participants who have T3 thyrotoxicosis (i.e TSH \<LLN, FT3 \> ULN and ≤5× ULN, but FT4 within normal range) at the Screening Visit may be enrolled, if they have serologically confirmed GD as per Inclusion Criterion 1.
• •Are willing and capable of giving written informed consent, which includes being able to comply with all aspects of the study treatment and testing schedule.